Clinical trials: Eyes With Glaucoma
Glaucoma Eye, Macular Degeneration
Retinal Oxygenation Estimation Trial With Mantis Photonics Hyperspectral Camera
An explorative study of the Mantis Photonics hyperspectral camera for retinal imaging and estimation of retinal oxygenation. Primary objective: To evaluate the performance of the hyperspectral camera for non-invasive retinal…
- Conditions
- Glaucoma Eye, Macular Degeneration, Macula Abnormality, Retinal Detachment
- Trial name
- NCT05566626
- Testing
- Hyperspectral retinal image, Mydriacyl Ophthalmic Product
- Where
- Sweden
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mantis Photonics AB
Open-angle Glaucoma
A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution
The purpose of this study was to assess the pigmentation in the trabecular meshwork of patients who had been treated for at least 2 years with TRAVATAN compared with patients without exposure (or less than 1 month) to a…
- Trial name
- NCT01485822
- Testing
- Trabecular Meshwork Tissue Collection, Travoprost 0.004% ophthalmic solution
- Volunteers
- 88 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Effects of Travatan Z and Xalatan on Ocular Surface Health
The purpose of this randomized, double-masked, parallel-group, multicenter study is to evaluate ocular surface effects after the administration of travoprost with SofZia® preservative system or Xalatan once daily for 12 weeks.
- Trial name
- NCT00708422
- Testing
- Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®), Latanoprost ophthalmic solution 0.005% (XALATAN®)
- Volunteers
- 231 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle Glaucoma Eye
MINIject (MINI SO627) in Patients With Open Angle Glaucoma Using Single Operator Delivery Tool
The study will assess safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a MINIject glaucoma implant.
- Trial name
- NCT04517786
- Testing
- MINIject CS627 implant
- Where
- 2 sites in India, Panama
- Volunteers
- 21 people
- Sponsor
- iSTAR Medical
Primary Open-Angle Glaucoma (POAG)
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
The present trial is planned to investigate and identify the best dosage of investigational drugs with respect to the treatment of open-angle glaucoma.
- Trial name
- NCT06903156
- Testing
- Mexidol
- Where
- 7 sites in Russia
- Volunteers
- 102 people
- Sponsor
- Pharmasoft
Glaucoma
Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma
This is a prospective, multicenter, single-arm clinical study to evaluate the safety and effectiveness of Beacon Aqueous Microshunt in patients with refractory glaucoma.
- Trial name
- Beacon (NCT04072016)
- Testing
- Beacon Aqueous Microshunt
- Where
- 4 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- MicroOptx
Primary Open Angle Glaucoma (POAG)
Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma.
- Trial name
- NCT07147647
- Testing
- Direct Selective Laser Trabeculoplasty
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Select Eye Care
Glaucoma, Ocular Hypertension
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of…
- Trial name
- NCT01254604
- Testing
- Preservative-Free Tafluprost or vehicle, Preservative-Free Timolol maleate
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma, Open-Angle
Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)
First, to compare safety and effectiveness outcomes for canaloplasty and trabeculotomy using the OMNI Surgical System to implantation of the iStent inject in lowering intraocular pressure (IOP) in pseudophakic eyes with open…
- Trial name
- NCT04658095
- Testing
- Canaloplasty and trabeculotomy with the OMNI system., iStent inject, Canaloplasty
- Where
- 5 sites in Germany, Spain and 1 more
- Volunteers
- 10 people
- Sponsor
- Sight Sciences, Inc.
Open-angle Glaucoma, Ocular Hypertension
IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with…
- Trial name
- NCT00527501
- Testing
- Travoprost/brinzolamide
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Timolol ophthalmic solution 0.5%, in IOP(intraocular pressure ) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a…
- Trial name
- NCT01342094
- Testing
- DE-111 ophthalmic solution, Timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Glaucoma, Open-Angle
AqueSys Microfistula Implant in Refractory Glaucoma
To establish the safety and performance of the AqueSys Microfistula Implant in eyes with refractory glaucoma.
- Trial name
- NCT01640756
- Testing
- AqueSys Microfistula Implant
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- AqueSys, Inc.
Ocular Hypertension, Open-angle Glaucoma
A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months
A double-masked, parallel study of AR-12286 Ophthalmic Solution 0.5%, or 0.7% (q.d., PM) or timolol maleate Ophthalmic Solution, 0.5% (b.i.d.), O.U. for 3 months.
- Trial name
- NCT01699464
- Testing
- AR-12286 Ophthalmic Solution 0.7%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Volunteers
- 211 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension, Open-Angle Glaucoma
The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma
The objective of this study is to investigate corneal confocal microscopic findings, ocular signs and symptoms in patients on treatment with the preserved prostaglandin analogue latanoprost 0.005% eye drops (Xalatan®) and after…
- Trial name
- NCT01369771
- Testing
- Tafluprost 0.0015%
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- FinnMedi Oy
Open Angle Glaucoma (OAG), Ocular Hypertension (OH)
Evaluate Efficacy, Safety, Tolerability and Biodegradation of PA5346 Ocular Implant in Patients With Open-Angle Glaucoma or Ocular Hypertension
The goal of this clinical study is to learn how effective and safe is a single administration of PA5346 Ocular Implant for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT06964061
- Testing
- PA5436 Ocular Implant, 115mcg
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- PolyActiva Pty Ltd
Open-angle Glaucoma
Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost
Evaluation of the intraocular pressure (IOP) lowering effect of two iStent inject devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to…
- Trial name
- NCT01444040
- Testing
- iStent inject, Travoprost
- Where
- Armenia
- Volunteers
- 196 people
- Sponsor
- Glaukos Corporation
Open-angle Glaucoma or Ocular Hypertension
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of four concentrations of DE-117 ophthalmic solution.
- Trial name
- NCT01868126
- Testing
- DE-117 ophthalmic solution, latanoprost ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 91 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Evaluating the safety and tolerability of QLS-101 versus timolol maleate ophthalmic solution in glaucoma or ocular hypertension.
- Trial name
- NCT04830397
- Testing
- QLS-101, Timolol Maleate
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Qlaris Bio, Inc.
Primary Open Angle Glaucoma
Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma
It is an interventional study for the treatment of Primary Open-Angle Glaucoma (POAG) using the Hexiris Microinvasive Scleral Trephine (MIST) system. This medical device includes a sclerectomy punch and injector assembly.
- Trial name
- NCT07358650
- Testing
- Hexiris Microinvasive Scleral Trephine (MIST)
- Where
- 5 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Hexiris Inc
Normal Eyes, Eyes With Glaucoma
OCT Agreement and Precision Study
To demonstrate clinical substantial equivalence of 3D OCT-1 Maestro as comparable to the commercially available iVue and NW-300.
- Conditions
- Normal Eyes, Eyes With Glaucoma, Eyes With Retinal Disease
- Trial name
- NCT02045823
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.